Authors:
A Broeks, MK Schmidt, ME Sherman, FJ Couch, JL Hopper, GS Dite, C Apicella, LD Smith, F Hammet, MC Southey, LJ Van 't Veer, R de Groot, VTHBM Smit, PA Fasching, MW Beckmann, S Jud, AB Ekici, A Hartmann, A Hein, R Schulz-Wendtland, B Burwinkel, F Marme, A Schneeweiss, H-P Sinn, C Sohn, S Tchatchou, SE Bojesen, BG Nordestgaard, H Flyger, DD Ørsted, D Kaur-Knudsen, RL Milne, JIA Pérez, P Zamora, PM Rodríguez, J Benítez, H Brauch, C Justenhoven, Y-D Ko, Genica Network, U Hamann, H-P Fischer, T Brüning, B Pesch, J Chang-Claude, S Wang-Gohrke, M Bremer, JH Karstens, P Hillemanns, T Dörk, HA Nevanlinna, T Heikkinen, P Heikkilä, C Blomqvist, K Aittomäki, K Aaltonen, A Lindblom, S Margolin, A Mannermaa, V-M Kosma, JM Kauppinen, V Kataja, P Auvinen, M Eskelinen, Y Soini, G Chenevix-Trench, AB Spurdle, J Beesley, X Chen, H Holland, kConFab, AOCS, D Lambrechts, B Claes, T Vandorpe, P Neven, H Wildiers, D Flesch-Janys, R Hein, T Löning, M Kosel, ZS Fredericksen, X Wang, GG Giles, L Baglietto, G Severi, C McLean, CA Haiman, BE Henderson, L Le Marchand, LN Kolonel, GG Alnæs, V Kristensen, A-L Børresen-Dale, DJ Hunter, SE Hankinson, IL Andrulis, AM Mulligan, FP O'Malley, P Devilee, PEA Huijts, RAEM Tollenaar, CJ Van Asperen, CS Seynaeve, SJ Chanock, J Lissowska, L Brinton, B Peplonska, J Figueroa, XR Yang, MJ Hooning, A Hollestelle, RA Oldenburg, A Jager, M Kriege, B Ozturk, GJLH van Leenders, P Hall, K Czene, K Humphreys, J Liu, A Cox, D Connley, HE Cramp, SS Cross, SP Balasubramanian, MWR Reed, AM Dunning, DF Easton, MK Humphreys, C Caldas, F Blows, K Driver, E Provenzano, J Lubinski, A Jakubowska, T Huzarski, T Byrski, C Cybulski, B Gorski, J Gronwald, P Brennan, S Sangrajrang, V Gaborieau, C-Y Shen, C-N Hsiung, J-C Yu, S-T Chen, G-C Hsu, M-F Hou, C-S Huang, H Anton-Culver, A Ziogas, PDP Pharoah, M Garcia-Closas
Journal name: 
Hum Mol Genet
Citation info: 
20(16):3289-3303
Abstract: 
Breast cancers demonstrate substantial biological, clinical and etiological heterogeneity. We investigated breast cancer risk associations of eight susceptibility loci identified in GWAS and two putative susceptibility loci in candidate genes in relation to specific breast tumor subtypes. Subtypes were defined by five markers (ER, PR, HER2, CK5/6, EGFR) and other pathological and clinical features. Analyses included up to 30 040 invasive breast cancer cases and 53 692 controls from 31 studies within the Breast Cancer Association Consortium. We confirmed previous reports of stronger associations with ER+ than ER- tumors for six of the eight loci identified in GWAS: rs2981582 (10q26) (P-heterogeneity = 6.1 × 10(-18)), rs3803662 (16q12) (P = 3.7 × 10(-5)), rs13281615 (8q24) (P = 0.002), rs13387042 (2q35) (P = 0.006), rs4973768 (3p24) (P = 0.003) and rs6504950 (17q23) (P = 0.002). The two candidate loci, CASP8 (rs1045485, rs17468277) and TGFB1 (rs1982073), were most strongly related with the risk of PR negative tumors (P = 5.1 × 10(-6) and P = 4.1 × 10(-4), respectively), as previously suggested. Four of the eight loci identified in GWAS were associated with triple negative tumors (P ≤ 0.016): rs3803662 (16q12), rs889312 (5q11), rs3817198 (11p15) and rs13387042 (2q35); however, only two of them (16q12 and 2q35) were associated with tumors with the core basal phenotype (P ≤ 0.002). These analyses are consistent with different biological origins of breast cancers, and indicate that tumor stratification might help in the identification and characterization of novel risk factors for breast cancer subtypes. This may eventually result in further improvements in prevention, early detection and treatment.
DOI: 
http://doi.org/10.1093/hmg/ddr228
Research group: 
Caldas Group
E-pub date: 
15 Aug 2011